Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opticept: CellCept Dosing Regimens in Kidney Transplant
NCT00087581Phase 4Completed
- Sponsor
- Roche
- Start
- Jun 2004
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycophenolate mofetil in kidney transplant rejection (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Treatment Failure During 12 Months Post-Transplantation and Percent Change from Baseline in Calculated Glomerular Filtration Rate (GFR) at 12 months. Started Jun 2004; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00087581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087581.